Recent Updates
Recently added Catalysts

bion

Phase 3

Urinary Incontinence | Unknown | Nephrology |Boston Scientific Corporation|Last Updated: Nov 19, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedSHAM_CONTROLLEDBiomarker
Total Trials1
Total Enrollment148
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00080470An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge IncontinencePHASE3 COMPLETED 148Jun 1, 2003Dec 1, 2012Nov 19, 201311 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Leaks Per Day
12 months
Freedom From Major Complications
5 years
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1EXPERIMENTALStimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
2SHAM_COMPARATORNo Stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.
Interventions
NameTypeDescription
bionDEVICEbattery powered microstimulator
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites11

Key Inclusion Criteria: 1. Age 18 years and above. 2. Diagnosed with urinary urge incontinence. 3. Have no reported history of urethral obstruction/stricture, bladder calculi or bladder tumor. 4. Have normal upper urinary tract function. 5. Be capable of giving informed consent. 6. Be capable and w...

Countries:United States
Unlock Eligibility Criteria